Latest Press Releases

Press Release Jun 24, 2024
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
Press Release Jun 20, 2024
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
Press Release Jun 11, 2024
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
Press Release Jun 4, 2024
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
Press Release May 29, 2024
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

Novel Host-Mimetic, Virus Killing Technology Platform
Press Release May 23, 2024
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
Press Release May 20, 2024
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others
Press Release May 15, 2024
NanoViricides Has Filed its Quarterly Report

NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection
Press Release May 14, 2024
A Novel Broad-Spectrum Antiviral with Activity Against RSV

Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment
Press Release May 10, 2024
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
Press Release May 8, 2024
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides
Press Release May 6, 2024
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides
Press Release Apr 30, 2024
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
Press Release Feb 15, 2024
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
Press Release Feb 1, 2024
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
Press Release Jan 29, 2024
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
Press Release Jan 4, 2024
NanoViricides to Present at the Biotech Showcase in San Fransisco
Press Release Nov 28, 2023
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
Press Release Nov 15, 2023
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
Press Release Nov 14, 2023
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
Press Release Oct 16, 2023
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
Press Release Oct 12, 2023
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
Press Release Aug 21, 2023
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
Press Release Jul 11, 2023
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
Press Release Jul 6, 2023
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
Press Release Jun 29, 2023
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
Press Release May 31, 2023
NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
Press Release May 16, 2023
NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
Press Release Apr 25, 2023
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Press Release Apr 17, 2023
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
Press Release Apr 4, 2023
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
Press Release Feb 15, 2023
NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
Press Release Jan 4, 2023
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
Press Release Dec 5, 2022
NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET
Press Release Nov 15, 2022
NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage
Press Release Oct 14, 2022
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage
Press Release Aug 9, 2022
NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy
Press Release Aug 4, 2022
NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus
Press Release May 17, 2022
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
Press Release Apr 25, 2022
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
Press Release Feb 15, 2022
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
Press Release Nov 16, 2021
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
Press Release Nov 15, 2021
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
Press Release Oct 13, 2021
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
Press Release Oct 11, 2021
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
Press Release May 17, 2021
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND
Press Release Mar 9, 2021
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application
Press Release Mar 2, 2021
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application
Press Release Feb 17, 2021
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND
Press Release Feb 8, 2021
NanoViricides’s Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies